Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Why The Mesoblast (ASX:MSB) Share Price Is Down

The Mesoblast Limited (ASX: MSB) share price is down around 2.5% after announcing its March 2019 update.

Mesoblast is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.

What Did Mesoblast report?

For the nine months of FY19 the company reported lower revenue of US$14.7 million compared to US$15.6 million in the first nine months of FY18. However, Mesoblast did say that royalty income on sales of TEMCELL for aGVHD in Japan increased by 28%.

There was a 29% reduction in net operating cash outflows to US$38.7 million for the nine months to March 2019. The company had cash reserves of US$70.4 million at the end of March 2019, with an additional US$35 million potentially available under existing arrangements from Hercules Capital and NovaQuest Capital.

The after tax loss of US69.1 million in the nine months to March 2019 compares to an after tax loss of US$14.5 million in the first nine months of FY18.

Mesoblast revealed that it has invested an additional US$9.5 million for commercial manufacturing to support the potential launch of the aGVHD product.

The company also reminded investors that the United States Food and Drug Administration (FDA) has agreed to a rolling Biologics License Application (BLA) review of remestemcel-L for the treatment of steroid-refractory acute Graft Versus Host Disease in children. The first module has been lodged and the process will allow the company to address any substantial matters raised by the FDA.

I don’t know much about Mesoblast or the industry it operates in, so that’s why I don’t think I can ever invest in it – it’s not in my circle of competence. I think the rapid growth shares in the free report below could be better ideas.

[ls_content_block id=”14947″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content